Hodgkin lymphoma (HL) is curable in 70-80% of patients with first-line therapy. However, relapses occur in a minority of patients with favorable early stage disease and are more frequent in patients with advanced HL. Salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant (ASCT) for patients with chemotherapysensitive disease is a standard treatment sequence for relapsed or refractory (rel/ref) HL. Patients who achieve complete response prior to ASCT have better survival outcomes. The choice of salvage chemotherapy therapy is becoming increasingly difficult in the era of novel agents, as there are no randomized studies to guide the choice of a second-line regimen. In this article, we will review current salvage therapy options, including combination chemotherapy and novel-agent-based salvage regimens for rel/ref HL.
Introduction
Classical Hodgkin lymphoma (HL) accounts for about 10% of all lymphomas, with approximately 9000 new cases in the United States in 2013 and 1200 deaths. 1 HL shows bimodal distribution of patients diagnosed between 15 and 30 years of age and in adults older than 55 years of age. The disease is curable in approximately 70-80% of patients with long-term overall survival rates of over 70% at 5 years in patients treated with standard chemotherapy regimens, including adriamycin, bleomycin, vinblastine, dacarbazine (ABVD) or Stanford V. [2] [3] [4] However, relapses occur in 10-20% of patients with favorable features and early stage disease (stage I-II) and 30-40% of patients with advanced disease. 5 Standard treatment for patients with relapsed or primary refractory (rel/ref) HL is salvage chemotherapy followed by high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) in chemotherapy-sensitive patients. The two randomized phase III clinical trials by the German Hodgkin Lymphoma Study Group (GHSG)/European Group for Blood and Marrow Transplantation and British National Lymphoma Investigators demonstrated significant improvement in progression-free survival (PFS) for patients with relapsed or refractory HL who underwent HDT/ASCT as compared with conventional second-line chemotherapy alone. Complete response (CR) to salvage therapy prior to ASCT is the strongest prognostic factor for post-ASCT outcome, with patients in CR at the time of ASCT having significantly superior PFS compared with patients not in CR. [6] [7] [8] [9] [10] [11] Overall response rates (ORRs) and CR rates vary according to salvage regimen and also based on whether positron emission tomography (PET) or computed tomography (CT) imaging was used for evaluation of response. Response status based on functional imaging with PET prior to ASCT had predictive values by identifying patients as poor risk if PET was positive after the salvage regimen. 9, 12, 13 In this article, we will review current salvage therapy options for rel/ref HL, including combination chemotherapy regimens and salvage regimens containing novel agents. regimens for patients with rel/ref HL include platinum-based and gemcitabine-based combination chemotherapy, and are listed in Table 1 Gemcitabine-based combinations are also commonly used as second-line or third-line salvage regimens, including GVD (gemcitabine, vinorelbine, liposomal doxorubicin) which produced an ASCT, autologous stem cell transplantation; HDT, high-dose therapy; HL, Hodgkin lymphoma. Table 1 . Salvage regimens for relapsed classical Hodgkin lymphoma. There are two phase II studies that have studied a response-adapted approach incorporating BV into second-line therapy for rel/ref HL. A multicenter phase II study evaluating BV as a second-line therapy prior to HDT/ASCT demonstrated an ORR of 68% to four cycles of BV alone. PET-negative CR was achieved in 35% of patients, who proceeded directly to HDT/ ASCT. In patients who continued to have FDGavid HL after four cycles of BV, an additional 61% of patients were able to achieve PET-negative CR after treatment with combination chemotherapy (ICE/DICE/IGEV/GND). Overall, 86% of patients were able to proceed to ASCT in the study, and 2-year post-ASCT PFS and OS were 72% and 94%, respectively. 29, 30 Similarly, Moskowitz and colleagues demonstrated safety and activity of single-agent BV as second-line therapy in 45 patients. PET-negative CR was achieved in 27% after two cycles of BV, and these patients proceeded directly to HDT/ASCT. Patients with PET-positive disease after BV treatment received two cycles of augmented ICE chemotherapy with 69% subsequently achieving CR. Ultimately, 44 of 45 patients who completed treatment were able to undergo ASCT. 31 In an attempt to improve response rates to second-line chemotherapy-based salvage regimens, addition of BV to chemotherapy in rel/ref HL has been evaluated in multiple clinical trials. BV plus ESHAP was evaluated in a phase II clinical trial by Garcia-Sanz and colleagues. A total of 66 patients were treated with BV-ESHAP with an observed ORR of 96% and CR of 70%. Overall, 61 patients proceeded to HDT/ASCT and the 1-year post-ASCT PFS was estimated at 87%. 32
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The addition of BV concurrently with ICE (BV-ICE) chemotherapy was evaluated in 16 patients with relapsed/refractory HL and preliminary results were presented at the 2016 American Society of Hematology (ASH) annual meeting. BV-ICE produced an ORR 94% and CR rate of 88% by investigator assessment and CR 69% by central independent radiographic review. Grade 3-4 myelosuppression was reported in 12% and peripheral neuropathy was seen in 31% of patients. A total of 94% of patients underwent stem cell collection and 75% were able to proceed to ASCT. Median follow up was 6.5 months (range 2-20 months) with three (19%) relapses observed during this time. 33 The combination of BV with DHAP as a secondline salvage therapy was evaluated by Hagenbeek and colleagues in a phase 1 dose-escalation trial for rel/ref HL. All 12 patients on the study achieved CR with median follow up of 15.4 months. High rates of grade 3-4 myelosuppression were reported. 34 A phase 1/2 study evaluated the combination of BV plus bendamustine as second-line salvage therapy in 53 evaluable patients with rel/ref HL. The combination produced an ORR of 93% with a CR rate of 74%. Patients were not required to proceed to HDT/ASCT after BV plus bendamustine, and the estimated 12-month PFS was 80% for both transplanted patents (n = 40) and the overall study population. 35 In addition to BV, inhibitors of the programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) pathway are highly effective agents for the treatment of rel/ ref HL. The programmed death receptor-1 (PD-1) pathway is an immune checkpoint that normally serves to dampen immune responses in tissues. PD-1 is expressed on activated T-cells and binds its ligands, PD-L1 and PD-L2, on tissue cells or antigen presenting cells to decrease T-cell activation, proliferation, and survival. 36 Tumor cells can co-opt this pathway to evade attack by the host immune system. 36 In particular, the PD-1/PD-L1 pathway appears to play a critical role in the pathogenesis of HL. Frequent genetic alterations of the 9p24.1 region, which includes the PD-L1/PD-L2 loci, are observed in HL cell lines and patient tumor samples, and PD-L1 expression on Reed-Sternberg cells in nearly universal in patients with HL. 37 Preliminary results from a phase I/II study of BV in combination with the PD-1 inhibitor, Bendamustine used as a single agent in patients who have progressed after multiple lines of therapy has produced ORRs of 50-53% and CR rates of 29-33%, though the duration of response is short, with median PFS reported to be 5.7 months but 10.2 months in patients with CR. 39 Patients that relapsed within 3 months of ASCT had no response to bendamustine. Grade 3 or higher adverse events included thrombocytopenia (20%), anemia (14%), and infection (14%).
Overall, 20% of patients were able to proceed to allogeneic stem cell transplant (alloHCT) after treatment with bendamustine. 24, 40 Patients who have relapsed after BV may also benefit from bendamustine. 41 Other single-agent chemotherapy agents have been studies in rel/ref HL, and include gemcitabine, doxil, vinorelbine, and vinblastine, with observed response rates in the 30-72% range. [42] [43] [44] [45] Novel agents for salvage of relapsed HL after ASCT The original pivotal phase II study of BV in patients with rel/ref HL after HDT/ASCT demonstrated an ORR of 75% and CR rate of 34%. Patients who achieved CR had median PFS of 20.5 months. 46 Chen and colleagues recently presented long-term outcomes for patients treated with BV after failure of ASCT in relapsed and refractory HL. At 5 years, overall OS was 41% and PFS was 22%. Patients who achieved CR with BV had improved survival with estimated OS and PFS rates of 64% and 52%, respectively. Patients responding to treatment who had a suitable stem cell donor, proceeded to alloHCT. Among patients who achieved CR, 38% continued to be in remission beyond 5 years. 47 Of note, retreatment with BV after BV discontinuation has been studied in patients who previously responded to BV producing an ORR of 60%, suggesting that BV can be used as a salvage option in prior BV responders. 48 Like BV, PD-1 inhibitors are effective treatment for patients who have failed HDT/ASCT. Ansell and colleagues reported the results of a phase Ib study of nivolumab in heavily pretreated HL patients, demonstrating an ORR of 87%, with a CR rate of 17%. 49 At a median follow up of 40 weeks, the rate of PFS at 24 weeks was 86% and median OS has not been reached. A subsequent phase II study of nivolumab in 80 patients who failed ASCT as well as prior BV confirmed a high ORR of 66%, with 9% of patients having a CR per independent review. Notably, the majority of responders remained in remission at the time of censoring, thus a significant proportion of responses appear to be durable. 50 Other novel treatment options that have been studied in patients who have relapsed after or were refractory to standard therapies include lenalidomide, alone or in combination with bendamustine, everolimus, and histone deacetylase (HDAC) inhibitors. Lenalidomide is an immunomodulatory agent that has shown activity in relapsed or refractory HL, with an ORR of 19% and CR rate of 3% in the largest study (n = 38) of heavily pretreated HL patients. 54 Addition of lenalidomide to bendamustine (Leben combination) showed an ORR of 75% with a CR rate of 44% and median PFS of 11 
Role of allogeneic stem cell transplantation in relapsed HL
Prior to development of novel agents, an alloHCT was the only curative option and could still benefit a subgroup of patients in rel/ref HL, such as patients who relapsed after HDT/ASCT or refractory disease to multiple lines of therapy. 61 Myeloablative conditioning is associated with decreased OS due to treatment-related mortality (TRM) 62 ; however, reduced intensity conditioning (RIC) regimens allow for decreased rates of TRM in patients undergoing alloHCT, though TRM still remains at around 15-25%. Patients who received alloHCT in CR have a significantly better outcome. Multiple studies have shown PFS and OS of about 30% after RIC. 63, 64 Patients that have failed multiple lines of therapy, including prior ASCT and BV therapy, but still show sensitive disease to salvage therapy should be considered for alloHCT.
Role of radiation therapy in the salvage setting
Radiation therapy alone (conventional or extended field) as a salvage modality in a relapsed HL can be considered in carefully selected patients that have not received radiation therapy as part of the initial therapy and if there are no adverse risk factors at the time of relapse. Older individuals, who lack constitutional symptoms with only limited stage disease and are not candidates for HDT/ASCT, can be offered radiation therapy as a salvage treatment modality. The GHSG demonstrated a 5-year FFTF of 28% and OS of 51% for second-line radiation therapy for relapsed HL. 65 Involved field radiation therapy (IFRT) can be added to second-line chemotherapy, with response rates reported of 88% when treated with ICE and IFRT. 14
Conclusions
In conclusion, there are abundant salvage therapy options for patients with rel/ref HL (Figure 1) . The goal of second-line salvage therapy, chemotherapy-based or with novel agents, is to achieve CR prior to HDT/ASCT, as PET-negative CR is strongly associated with a favorable post-ASCT outcome. The choice of salvage chemotherapy therapy is becoming increasingly difficult in the era of novel agents, as there are no randomized studies to guide the choice of a second-line regimen. At the present time, there is a range of chemotherapy-based and novel-agent-based salvage options that are acceptable for use in the second-line and can lead to excellent ORR and CR rates (Table 1 ). In the absence of comparative data, platinum-based combination salvage therapy remains the benchmark and standard option as a salvage regimen. However, with introduction of BV into second-line therapy, excellent response rates have been demonstrated, allowing patients to be bridged to ASCT with fewer side effects than conventional chemotherapy. As novel agents move into earlier lines of therapy (BV is currently under study as part of front-line therapy), it may be difficult to interpret data on BV-based second-line regimens in which patients were naïve to BV. Therefore, it will be important to study salvage regimens that incorporate other agents like PD-1 inhibitors, and BV-based salvage regimens in patients with prior BV exposure. In patients who are refractory to pre-ASCT therapy, have failed ASCT, or are ineligible for HDT/ASCT, chemotherapy or novel agents can provide disease control and palliation of symptoms, or can serve as a bridge to alloHSCT. These patients should be considered for enrollment in a clinical trial, as several promising new agents or combinations of novel agents are underway to optimize treatment options for patients with rel/ref HL.
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